3sbio, Inc. · HKEX:1530
3sbio — FY2025 Earnings Presentation
31 slides from 3sbio's earnings presentation, Mar 31, 2026
Slide 1: 2025 Annual Results Presentation
2025 Annual Results Presentation 3 1 st M a r c h , 2 0 2 6 1
Slide 2: Disclaimer
Disclaimer This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only. You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") befor
Slide 3: Agenda
Agenda 2025 AR Business R&D Financial Q&A Abstract Progress Review 1 2 3 4 5 3
Slide 4: 2025 AR Abstract
01 2025 AR Abstract 4
Slide 5: 2025 Annual Results Abstract
2025 Annual Results Abstract 17.7 20.4 CNY Bn 8.5 8.5 9.1 1.9 2.1 6.9 7.8 1.5 7.4 8.2 8.1 1.7 2.0 2.4 • Global partnership 2022 2023 2024 2025 2022 2023 2024 2025 2022 2023 2024 2025 2022 2023 2024 2025 comprehensively Net profit attributable to Net profit attributable boosts our revenue Revenue to
Slide 6: Business Overview
Business Overview 核心产品 Commercialization Revenue 8.0 Bn Licensing Revenue 9.4 Bn • License out the global rights of anti- PD1/VEGF BsAb SSGJ-707 to Pfizer • TPIAO (rhTPO), EPIAO&SEPO (rhEPO), Yisaipu, Mandi etc. products on sale; • TPIAO for CLDT indication approved for marketing, LIPORAXEL1 for GC
Slide 7: Expanding Commercialized Products Portfolio
Expanding Commercialized Products Portfolio New Products is Contributing New Income NuPIAO Loncipoetin α Injection Nephrology SSS20 Eltrombopag LIPORAXEL Hematology/ DB1303 Her-2 ADC Paclitaxel oral solution Oncology Listed in NRDL 613 Anti-IL-1β mAb Yisaituo Anti-IL-17A mAb 610 Anti-IL-5 mAb Autoim
Slide 8: Business Progress
02 Business Progress
Slide 9: Our Partnership with Pfizer
Our Partnership with Pfizer 707: PD-1&VEGF Bispecific Antibody A Potential Next-generation I/O Therapy 1.25 Bispecific Antibody with Tetravalent Structure: US$bn 4.8 +Each “arm” Double can bind both 100 up to 150 US$bn PD-1 and -Digit VEGF US$mn US$mn Up-front Payment Milestone Payment Royalties Sha
Slide 10: Supply Rights Outside of the US
Supply Rights Outside of the US FDA&EMA GMP standard 01 • Manufacture, examination, storage fully automated intelligent factory • High standard quality system Manufacturing Base of 75,000L+ biologics DS capacities 02 • 6*12,000L stainless steel bioreactors; Large-scale DS and DP • 3*1000L disposable
Slide 11: Update on the Collaboration
Update on the Collaboration Achieved Partnership in 2025 Smooth Progress in 2026 Development Milestones • 5 phase III global MRCT are planned to start from 2026, trigger milestone payments 1.5 1st 7 DS Supply • 2nd batch of 707 DS for global clinical trials Clinical Trials • 2nd wave clinical trials
Slide 12: 707 Clinical Strategy: Pipeline-in-a-Product
707 Clinical Strategy: Pipeline-in-a-Product 7 Plans of clinical Wave 1 Clinical Strategy trials published in 2025 Based on Chinses data, jumpstart phase III trial 3 Entered phase III Leading progress on NSCLC/ CRC indications MRCTs Planned to Initiate in 2026 with large market size 10+ indications
Slide 13: 707 Clinical Progress
707 Clinical Progress PF-08634404 Clinical Trial Plan (Primary Completion Date) Combo chemo 1L Sq & NSq NSCLC (Ph3，recruiting) 2029.02 OS, PFS Combo chemo 1L mCRC (Ph3，recruiting) 2030.03 PFS,OS 3 phase III pivotal 1L EC (Planned to initiate Ph3) trials started To be published recruiting 1L mUC (Pla
Slide 14: Return on Collaboration
Return on 707 Collaboration Registration Milestone Payments Trigger registration milestone payments when 707 approved for marketing in different countries or regions Royalties R&D Milestone Payments Tiered based on accumulated net sales Trigger development milestone payments when MRCT starts Sales M
Slide 15: 707: Potential Development Opportunities
707: Potential Development Opportunities THORACIC GENITOURINARY Nsq NSCLC：~104K US patients UC：~19K US patients Sq NSCLC： ~37K US patients RCC: ~16K US patients ES-SCLC：~33K US patients EC Potential to address 350K+ GASTROINTESTINAL OTHER CANCERS US patients GC CRC：~63K US patients ~80K+ US patients
Slide 16: a) ~ © o
a) 3 ~ © o
Slide 17: R&D Pipeline - 27 Candidates
R&D Pipeline - 27 Candidates Therapeutic Area Candidates Pre-clinical IND Ph I Ph II Ph III NDA SSS06 Long-acting rhEPO Approved Nephrology Remitch-CLD pruritus SSS55 C3b Bifunctional FP SSS68 Long-acting anti-April/BAFF BsAb U.S. IND 13 SSS20 Eltrombopag Approved IND& Phase I 707 anti-PD1/VEGF BsAb
Slide 18: 608 Approved for Marketing
608 Approved for Marketing Yisaituo® — Novel IL-17A mAb, New Treatment Target, New Flagship for Immunotherapy （Amdokitug Injection） Long Dosing Interval Sustained & Stable Efficacy Low Recurrence Rate Low Immunogenicity Good Local Tolerability Outstanding Safety no cases of 8 52 1 0 weeks treatment
Slide 19: SSS06 Approved for Marketing
SSS06 Approved for Marketing 1st domestic long-acting rhEPO (biweekly injection) NuPIAO (Loncipoetin α Injection) Excellent Efficacy and Safety Prominent long-acting advantages Compared with short-acting EPO By optimizing the molecular structure (EPIAO), NuPIAO has equivalent and prolonging the half
Slide 20: Selected Pipeline
Selected Pipeline Code Candidate Indication Pre-IND Phase I Phase II Phase III NDA Only actively ongoing 705 Anti-PD1/HER2 BsAb HER2+ Solid Tumors clinical trial in China Advanced NSCLC 706 Anti-PD1/PDL1 BsAb Advanced GC 708 Anti-PD1/TGFβ BsAb Solid Tumors 709 Anti-PD1/LAG3 BsAb Solid Tumors Anti-B7
Slide 21: Selected Pipeline of Autoimmune
Selected Pipeline of Autoimmune Code Target Indication Pre-IND Phase I Phase II Phase III NDA AG NDA Accepted 613 IL1β mAb PGF Adult AD Monotherapy NDA Accepted Adult AD with TCS CRSwNP AD full population 611 IL4Rα mAb coverage Adolescent AD COPD Pediatric AD Ranks NO.1 progress in China 610 IL5 mAb
Slide 22: Selected Early-stage Candidates: Cover Broad Autoimmune Diseases
Selected Early-stage Candidates: Cover Broad Autoimmune Diseases SSGJ-717 SSGJ-718 SSGJ-719 SSGJ-629 Anti-TSLP/IL-4R BsAb Anti-CD3/BCMA/CD19 TsAb Anti-TL1A/IL-23p19 inhalation IL-23R Oral Peptide TCE Drug BsAb administration Est. indication: SLE/LN/RA Est. indication: IBD Est. indication: Asthma COP
Slide 23: R&D Centers
R&D Centers Shen Yang Shang Hai Hang Zhou Dong Guan Shen Zhen Italy Biopharmaceuticals/ Biopharmaceuticals Small molecule CGT / mRNA Biopharmaceuticals DP small molecule Anchored in Needs FIC Innovation Modality Exploration AI Application Prioritizing the clinical value of Develop innovative drug co
Slide 24: Financial Review
03 Financial Review 24
Slide 25: 2025 Annual Results Abstract
2025 Annual Results Abstract CNY Bn Statement of Profit or Loss 2025 2024 YoY EPS Revenue 17.7 9.1 94.3% 3.51 RMB/share Gross profit 16.3 7.8 108.8% R&D costs 1.5 1.3 14.6% 2024 0.86 R&D costs ratio 8.6% 14.6% -- Net profit attributable to owners of the parent 8.5 2.1 305.8% 2025 3.51 Net profit att
Slide 26: Improved R&D Costs, Increased Finance Income
Improved R&D Costs, Increased Finance Income Selling and Administrative Comprehensive R&D Costs Distribution Expenses Expenses Finance Costs 1.5 Bn 3.6 Bn 651 Mn 227 Mn YOY 14.6% YOY 8.3% YOY 29.7% Positive contribution R&D costs Administrative Comprehensive increased CNY Bn expenses increased CNY M
Slide 27: Asset Scale Reaches a New High, Ample Financial Resource Supports Development
Asset Scale Reaches a New High, Ample Financial Resource Supports Development Asset Scale Reaches a New High 36.3 Bn 400 Total Assets Net Assets 350 300 250 30.4 Bn 200 150 100 2021 2022 2023 2024 2025 Gearing Ratio Decreased to a Lowest Level 9.8% Financial Resource Gearing Ratio 230 51% 180 204 41
Slide 28: BD Strategy
BD Strategy Sufficient Financial Resource Strong cash flow generation R&D Support capacity Near 800 scientists, accounting for over 20% of total staff; R&D expense ratio surpass 10% Flexible Collaboration Structures License-in, CSO, CDMO, license- out, investment, M&A etc. Manufacturing Capabilitie
Slide 29: Revenue Momentum Expected to Continue
Revenue Momentum Expected to Continue 2025 2026-2029 est. 2030~ est. New Launches Loncipoetin α Injection, Next Wave Innovation Amdokitug Injection, 705, 706, 708, 709, IL-1β, IL-4Rα, IL-5 mAbs SPGL008, SSS59, 626, 627 HER2 ADC2, Clifutinib3… and more Combined Development, regulatory Double-digit ro
Slide 30: Q&A
05 Q&A
Slide 31: THANKS
THANKS 3SBio Inc. (1530.HK) Investor Relations ir@3sbio.com 珍 爱 生 命 · 关 注 生 存 · 创 造 生 活 CHERISH LIFE CARE FOR LIFE CREATE LIFE